FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 299:980-985 November 2, 1978 Number 18 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To detect familial medullary thyroid carcinoma in a premetastatic stage, we administered tests provocative of calcitonin secretion (infusion of calcium or pentagastrin or both) each year for seven years to members of a pedigree now numbering 107. Since 1970, 21 patients converted from normal to abnormal secretory responses (two separate tests in which calcitonin levels exceeded 0.58 ng per milliliter). Twenty of 21 glands removed showed C-cell hyperplasia, and eight of the 20 also showed foci of carcinoma. As compared to the 12 patients with tumors detected during the first year of screening, all of whom had bilateral carcinoma (seven of 12 with local metastases), later carcinomas were smaller (mean diameter of 0.2 vs. 0.8 cm), were unilateral (in all but two cases) and occurred in younger patients (mean age of 14.9 vs. 36.4 years), and none had detectable metastases.

This article has been cited by other articles:

• Cascon, A., Cebrian, A., Pollan, M., Ruiz-Llorente, S., Montero-Conde, C., Leton, R., Gutierrez, R., Lesueur, F., Milne, R. L., Gonzalez-Albarran, O., Lucas-Morante, T., Benitez, J., Ponder, B. A. J., Robledo, M. (2005). Succinate Dehydrogenase D Variants Do Not Constitute a Risk Factor for Developing C Cell Hyperplasia or Sporadic Medullary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 90: 2127-2130 [Abstract] [Full Text]  
• Cote, G. J., Gagel, R. F. (2003). Lessons Learned from the Management of a Rare Genetic Cancer. NEJM 349: 1566-1568 [Full Text]  
• Diaz-Cano, S. J., de Miguel, M., Blanes, A., Tashjian, R., Wolfe, H. J. (2001). Germline RET 634 Mutation Positive MEN 2A-related C-Cell Hyperplasias Have Genetic Features Consistent with Intraepithelial Neoplasia. J. Clin. Endocrinol. Metab. 86: 3948-3957 [Abstract] [Full Text]  
• Erdogan, M. F., Gullu, S., Baskal, N., Uysal, A. R., Kamel, N., Erdogan, G. i (1997). Omeprazole: Calcitonin Stimulation Test for the Diagnosis Follow-Up and Family Screening in Medullary Thyroid Carcinoma. J. Clin. Endocrinol. Metab. 82: 897-899 [Abstract] [Full Text]  
• Horvit, P. K., Gagel, R. F. (1997). The Goitrous Patient with an Elevated Serum Calcitonin--What to Do?. J. Clin. Endocrinol. Metab. 82: 335-337 [Full Text]  
• Hollenberg, C. H. (1983). Medullary Carcinoma of the Thyroid. Arch Otolaryngol Head Neck Surg 109: 103-105 [Abstract]  
• Block, M. A., Jackson, C. E., Greenawald, K. A., Yott, J. B., Tashjian, A. H. Jr (1980). Clinical Characteristics Distinguishing Hereditary From Sporadic Medullary Thyroid Carcinoma: Treatment Implications. Arch Surg 115: 142-148 [Abstract]